These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 34569969)
1. Interrogation of Dystrophin and Dystroglycan Complex Protein Turnover After Exon Skipping Therapy. Novak JS; Spathis R; Dang UJ; Fiorillo AA; Hindupur R; Tully CB; Mázala DAG; Canessa E; Brown KJ; Partridge TA; Hathout Y; Nagaraju K J Neuromuscul Dis; 2021; 8(s2):S383-S402. PubMed ID: 34569969 [TBL] [Abstract][Full Text] [Related]
2. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting. Maruyama R; Yokota T Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217 [TBL] [Abstract][Full Text] [Related]
3. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy. van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788 [TBL] [Abstract][Full Text] [Related]
4. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998 [TBL] [Abstract][Full Text] [Related]
5. Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice. Vila MC; Novak JS; Benny Klimek M; Li N; Morales M; Fritz AG; Edwards K; Boehler JF; Hogarth MW; Kinder TB; Zhang A; Mazala D; Fiorillo AA; Douglas B; Chen YW; van den Anker J; Lu QL; Hathout Y; Hoffman EP; Partridge TA; Nagaraju K J Pathol; 2019 Jul; 248(3):339-351. PubMed ID: 30883742 [TBL] [Abstract][Full Text] [Related]
6. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression. Lee JJA; Saito T; Duddy W; Takeda S; Yokota T Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539 [TBL] [Abstract][Full Text] [Related]
7. Restoring Dystrophin Expression with Exon 44 and 53 Skipping in the DMD Gene in Immortalized Myotubes. Echigoya Y; Yokota T Methods Mol Biol; 2023; 2587():125-139. PubMed ID: 36401027 [TBL] [Abstract][Full Text] [Related]
8. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. Hanson B; Wood MJA; Roberts TC RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516 [TBL] [Abstract][Full Text] [Related]
9. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660 [TBL] [Abstract][Full Text] [Related]
10. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Echigoya Y; Yokota T Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394 [TBL] [Abstract][Full Text] [Related]
11. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results. van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725 [TBL] [Abstract][Full Text] [Related]